Recellularization via electroporation therapy of the duodenum combined with glucagon-like peptide-1 receptor agonist to replace insulin therapy in patients with type 2 diabetes: 12-month results of a first-in-human study.

MLA

Busch, Celine B. E., et al. “Recellularization via Electroporation Therapy of the Duodenum Combined with Glucagon-like Peptide-1 Receptor Agonist to Replace Insulin Therapy in Patients with Type 2 Diabetes: 12-Month Results of a First-in-Human Study.” Gastrointestinal Endoscopy, vol. 100, no. 5, Nov. 2024, pp. 896–904. EBSCOhost, https://doi.org/10.1016/j.gie.2024.04.2904.

APA

Busch, C. B. E., Meiring, S., van Baar, A. C. G., Holleman, F., Nieuwdorp, M., & Bergman, J. J. G. H. M. (2024). Recellularization via electroporation therapy of the duodenum combined with glucagon-like peptide-1 receptor agonist to replace insulin therapy in patients with type 2 diabetes: 12-month results of a first-in-human study. Gastrointestinal Endoscopy, 100(5), 896–904. https://doi.org/10.1016/j.gie.2024.04.2904

Chicago

Busch, Celine B E, Suzanne Meiring, Annieke C G van Baar, Frits Holleman, Max Nieuwdorp, and Jacques J G H M Bergman. 2024. “Recellularization via Electroporation Therapy of the Duodenum Combined with Glucagon-like Peptide-1 Receptor Agonist to Replace Insulin Therapy in Patients with Type 2 Diabetes: 12-Month Results of a First-in-Human Study.” Gastrointestinal Endoscopy 100 (5): 896–904. doi:10.1016/j.gie.2024.04.2904.